Mark Stein, PhD, ABPP

Faculty Appointment(s)

Professor

Leadership Role(s)

Medical Director, DBD Program (Psychotherapy), Seattle Children's

mstein42@uw.edu

206-987-1161

UW Medicine profile » Seattle Children's profile »

Personal Statement

I am a Profesor of Psychiatry, Adjunct Professor of  Pediatrics, and a clinical researcher specializing in ADHD throughout the lifespan. I direct the PEARL Clinic (Program to enhance ​attention, regulation, and learning) at Seattle Children’s and Seattle Children’s at Overlake Hospital in Bellevue. The PEARL Clinic is based on a multidisciplinary and collaborative care model which works closely with PCP’s and schools. The majority of my clinical work involves  diagnostic evaluations and consultations. Treatment recommendations are made for the parents, referring physician, and schools. I also direct the clinical program for SEA STAR, a summer treatment program for children with ADHD and related disorders that targets social impairment and self-esteem, in collaboration with the UW Autism Center.

Comparative efficacy and personalized ADHD treatment are major themes of my work. I have published over 120 articles, mostly having to do with ADHD diagnosis and treatment in all ages, and specific areas within ADHD such as genetics, thyroid, and sleep . I have  participated in numerous clinical trials of stimulant  and non stimulant medications. Current research studies involve parents with ADHD, children with ADHD and Autism, and a new NIH sponsored study examining the effects of abruptly discontinuing methylphenidate in children with ADHD.

Other areas of interest include sleep problems and overlap with ADHD, pediatric psychology, and research ethics. Finally, I participate in the ITHS Treatment Innovatiopn Center, focusing on removing barriers to multi-site clinical and translational studies.

Department Affiliations

Training Programs

Recent Publications

Acute Effects of Parent Stimulant Medication Versus Behavioral Parent Training on Mothers' ADHD, Parenting Behavior, and At-Risk Children.
(2020 Sep 8)
J Clin Psychiatry 81(5):
Chronis-Tuscano A, French W, Strickland J, Sasser T, Gonzalez ENS, Whitlock KB, Stein MA
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors.
(2020 Sep 11)
J Clin Oncol
Apolo AB, Nadal R, Girardi DM, Niglio SA, Ley L, Cordes LM, Steinberg SM, Sierra Ortiz O, Cadena J, Diaz C, Mallek M, Davarpanah NN, Costello R, Trepel JB, Lee MJ, Merino MJ, Bagheri MH, Monk P, Figg WD, Gulley JL, Agarwal PK, Valera V, Chalfin HJ, Jones J, Streicher H, Wright JJ, Ning YM, Parnes HL, Dahut WL, Bottaro DP, Lara PN Jr, Saraiya B, Pal SK, Stein MN, Mortazavi A
Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy.
(2020)
Front Oncol 10(): 1381
Graff JN, Stein MN, Surana R, Al Rabadi L, Liu E, Fong L, Bailey S, Latour E, Newby TA, Moran AE, Beer TM
Seizure risk, methylphenidate, and ADHD: reassuring news.
(2020 Jun)
Lancet Child Adolesc Health 4(6): 409-410
Russell D, Stein MA
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
(2020 Feb 13)
Eur Urol Oncol
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ
Show complete publication list »